RGCC Oncocount is a follow-up tool for cancer patients undergoing treatment, offering insight into the effectiveness of therapies and monitoring disease progression. Circulating Tumor Cells (CTCs) serve as potent biomarkers, their presence in the bloodstream signaling a potential resurgence of cancer.
The RGCC Oncocount test serves as a monitoring tool utilized during and post-treatment to assess the effectiveness of your cancer therapy and facilitate early detection of recurrence or relapse. Enumerating circulating tumor cells (CTCs) acts as a prognostic factor, assisting clinicians in anticipating the disease progression and executing appropriate treatment approaches.
Oncocount used as a follow-up test offers insight into the effectiveness of cancer therapy and facilitates early detection of recurrence or relapse of several cancers.
The test applies to all types of cancers except the one in the central nervous system and is not just limited to the following.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
“RGCC’s Oncocount test is crucial for monitoring cancer recurrence and guiding long-term treatment strategies. Its precision enables proactive management, improving patient outcomes and quality of life. A vital component of comprehensive cancer care.”
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
A simple non-invasive test to monitor cancer.
We suggest undergoing followup tests every three months during active cancer treatment to evaluate the efficacy of the ongoing treatment plan.
Every 3 months for 1 year after completing the treatment to monitor for early relapse/recurrence. Once patients achieve full remission, the test is recommended every six months.
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Detect the potential recurrence of cancer early with precise monitoring of Circulating Tumor Cells (CTCs), you can take control of your cancer journey. RGCC Oncocount empowers clinicians and patients with proactive monitoring to stay ahead in your fight against cancer.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
© 2025 Neeli Genetics. All Rights Reserved.